Ligand Pharmaceuticals LGND Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's net gains (losses) on investments?
- Ligand Pharmaceuticals (LGND) reported net gains (losses) on investments of -$732K in Q1 2026.
- How has Ligand Pharmaceuticals's net gains (losses) on investments changed year-over-year?
- Ligand Pharmaceuticals's net gains (losses) on investments decreased by 3227.3% year-over-year, from -$22K to -$732K.
- What is the long-term trend for Ligand Pharmaceuticals's net gains (losses) on investments?
- Over 2 years (2021 to 2025), Ligand Pharmaceuticals's net gains (losses) on investments has grown at a -9.5% compound annual growth rate (CAGR), from -$221K to $181K.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.